[go: up one dir, main page]

EE05547B1 - Kristalliline efavirens - Google Patents

Kristalliline efavirens

Info

Publication number
EE05547B1
EE05547B1 EEP200000743A EEP200000743A EE05547B1 EE 05547 B1 EE05547 B1 EE 05547B1 EE P200000743 A EEP200000743 A EE P200000743A EE P200000743 A EEP200000743 A EE P200000743A EE 05547 B1 EE05547 B1 EE 05547B1
Authority
EE
Estonia
Prior art keywords
crystalline efavirenz
efavirenz
crystalline
Prior art date
Application number
EEP200000743A
Other languages
English (en)
Inventor
A. Radesca Lilian
B. Maurin Michael
R. Rabel Shelley
R. Moore James
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22214647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05547(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE200000743A publication Critical patent/EE200000743A/et
Publication of EE05547B1 publication Critical patent/EE05547B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EEP200000743A 1998-06-11 1999-06-10 Kristalliline efavirens EE05547B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8898198P 1998-06-11 1998-06-11
PCT/US1999/013199 WO1999064405A1 (en) 1998-06-11 1999-06-10 Crystalline efavirenz

Publications (2)

Publication Number Publication Date
EE200000743A EE200000743A (et) 2002-10-15
EE05547B1 true EE05547B1 (et) 2012-06-15

Family

ID=22214647

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000743A EE05547B1 (et) 1998-06-11 1999-06-10 Kristalliline efavirens

Country Status (21)

Country Link
EP (1) EP1086087A1 (et)
JP (1) JP2002517487A (et)
CN (1) CN1307568A (et)
AR (3) AR018670A1 (et)
AU (1) AU758114C (et)
BR (1) BR9911523A (et)
CA (1) CA2333550A1 (et)
EE (1) EE05547B1 (et)
HR (1) HRP990182A2 (et)
HU (1) HUP0103819A3 (et)
IL (1) IL139793A (et)
MY (1) MY126450A (et)
NO (1) NO20006255L (et)
NZ (1) NZ507713A (et)
PL (1) PL198504B1 (et)
SG (3) SG111981A1 (et)
SK (1) SK18182000A3 (et)
TW (1) TWI235152B (et)
UA (1) UA74324C2 (et)
WO (1) WO1999064405A1 (et)
ZA (1) ZA200006173B (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
US7205402B2 (en) * 2004-09-02 2007-04-17 Bristol-Myers Squibb Company Synthesis of a benzoxazinone
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz
US8222273B2 (en) * 2008-02-04 2012-07-17 Pfizer Limited Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN102924398B (zh) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
CA2898145C (en) * 2013-01-23 2021-08-31 Alienor Farma Increased dosage of efavirenz for the treatment of cancer
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
CN105001101B (zh) * 2015-05-28 2017-11-28 乐平市瑞盛制药有限公司 一种4‑氯‑2‑三氟乙酰基苯胺水合物盐酸盐的合成方法
CN108947855B (zh) * 2018-08-10 2021-10-22 江苏沙星化工有限公司 一种依非韦伦关键中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
AU3736197A (en) * 1996-07-26 1998-02-20 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same
KR100573192B1 (ko) * 1997-02-05 2006-04-24 머크 앤드 캄파니 인코포레이티드 역-용매를 사용한 역전사효소 억제제의 결정화 방법 및 당해 역전사효소 억제제의 결정형

Also Published As

Publication number Publication date
PL345221A1 (en) 2001-12-03
BR9911523A (pt) 2001-09-18
PL198504B1 (pl) 2008-06-30
AU758114C (en) 2003-10-30
NO20006255D0 (no) 2000-12-08
UA74324C2 (uk) 2005-12-15
AR077407A2 (es) 2011-08-24
NZ507713A (en) 2003-08-29
SG134977A1 (en) 2007-09-28
SG111981A1 (en) 2005-06-29
AU758114B2 (en) 2003-03-13
MY126450A (en) 2006-10-31
HRP990182A2 (en) 2000-02-29
CA2333550A1 (en) 1999-12-16
IL139793A0 (en) 2002-02-10
IL139793A (en) 2006-10-31
HUP0103819A2 (hu) 2002-02-28
ZA200006173B (en) 2001-10-31
AU4436499A (en) 1999-12-30
TWI235152B (en) 2005-07-01
AR077469A2 (es) 2011-08-31
CN1307568A (zh) 2001-08-08
EE200000743A (et) 2002-10-15
AR018670A1 (es) 2001-11-28
JP2002517487A (ja) 2002-06-18
SG111980A1 (en) 2005-06-29
WO1999064405A1 (en) 1999-12-16
NO20006255L (no) 2001-02-12
SK18182000A3 (sk) 2001-08-06
EP1086087A1 (en) 2001-03-28
HUP0103819A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE341990T1 (de) Sigmidoskop
DE69924838D1 (de) Einlasslufterhitzmodule
PT1119430E (pt) Fresa
ID23287A (id) Trisiklik tersubstitusi
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
DE59906732D1 (de) Verstellmechanismus
EE05547B1 (et) Kristalliline efavirens
ATE262513T1 (de) Benzoylpyridazine
DE69714228D1 (de) Kristalline metallophosphate
ID23219A (id) Trisiklik tersubstitusi
FI980222A0 (fi) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
PT1102747E (pt) Formas cristalinas do osanetant
DE59807217D1 (de) Nadellager
DE59808995D1 (de) Endomikroskopsystem
DE19842103B4 (de) Stanznietzuführung
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
FI980856A0 (fi) Andningsskydd utrustad med en identifierare
DE59912532D1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
PT1076660E (pt) (4-bromopirazol-3-il)-benzazolos substituidos
DE59901263D1 (de) Einzelplatz-sortierer
FI980053A0 (fi) Anordning foer utformande av fiberbollar av laongstraeckta fibrer som foeljer med enluftstroem
ATA126298A (de) Verpuffungsklappe
DE59900975D1 (de) Falzwalzenlagerung